Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis.

What the trial testedas reported · 2026

Not counted

−10%−18% to −1%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.90, 95% CI 0.82–0.99

the abstract, start to end

… in the ezetimibe-statin group with RR: 0.90, 95% CI: 0.82 - 0.99; P = 0.02.

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

RR 0.900.82–0.99

StatinsOther lipid agentsCardiovascular events

1 / 3